StreetInsider.com News Articles

Form 8-K Tempest Therapeutics, For: Feb 25

Wed, 25 Feb 2026 08:09:00 -0500

si-local-file:///var/storage/secattach/20260225/26055655.html

Form 8-K Tempest Therapeutics, For: Feb 25

Wed, 25 Feb 2026 08:09:00 -0500

si-local-file:///var/storage/secattach/20260225/26055655.html

Tempest reports 100% response rate in cancer therapy trial

Wed, 25 Feb 2026 07:59:32 -0500

Tempest Therapeutics (NASDAQ: TPST) reported interim results from its REDEEM-1 trial showing a 100% complete response rate among six patients with relapsed/refractory multiple myeloma treated with TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy.

The Brisbane, California-based biotechnology company said all six efficacy evaluable patients achieved complete responses according to International Myeloma Working Group criteria as of a January 31, 2026 data cutoff. Patients received treatment at two dose levels in the Phase 1/2a study.

The therapy demonstrated what the company described as a favorable safety profile, with no Grade 3 or higher cytokine release syndrome reported. One patient at the highest dose level

Tempest reports 100% response rate in cancer therapy trial

Wed, 25 Feb 2026 07:59:32 -0500

The therapy demonstrated what the company described as a favorable safety profile, with no Grade 3 or higher cytokine release syndrome reported. One patient at the highest dose level

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Wed, 25 Feb 2026 07:59:00 -0500

100% complete response (CR) rate among all six efficacy evaluable patients
Favorable safety profile with no Grade >3 CRS or ICANS
Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease
36 patients with relapsed/refractory multiple myeloma treated to date across two studies
Tempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026

BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Wed, 25 Feb 2026 07:59:00 -0500

100% complete response (CR) rate among all six efficacy evaluable patients
Favorable safety profile with no Grade >3 CRS or ICANS
Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease
36 patients with relapsed/refractory multiple myeloma treated to date across two studies
Tempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026

BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline

Form 8-K Tempest Therapeutics, For: Feb 11

Wed, 11 Feb 2026 07:14:00 -0500

si-local-file:///var/storage/secattach/20260211/25979319.html

Form 8-K Tempest Therapeutics, For: Feb 11

Wed, 11 Feb 2026 07:14:00 -0500

si-local-file:///var/storage/secattach/20260211/25979319.html

Tempest details strategy for advancing CAR-T therapy pipeline

Wed, 11 Feb 2026 06:59:25 -0500

Tempest Therapeutics Inc. (NASDAQ: TPST) outlined its development strategy for recently acquired CAR-T assets, emphasizing partner-funded programs to advance clinical trials while preserving internal capital.

The Brisbane, California-based biotechnology company plans to prioritize development of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy currently in Phase 1 clinical trials in China. The company expects to initiate a registrational Phase 2b trial in China by the end of 2026, with interim data anticipated in 2027. Development activities in China receive funding from a strategic partner.

Tempest disclosed TPST-4003, an in vivo CAR-T program designed to deliver the same dual-targeting CD19/BCMA construct without requiring ex vivo

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Wed, 11 Feb 2026 06:59:00 -0500

Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets
Development approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capital
Pipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones

BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a diversified portfolio of cell therapy and small molecule product candidates, today outlined its post-transaction strategy to advance its newly acquired CAR-T

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Wed, 11 Feb 2026 06:59:00 -0500

Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets
Development approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capital
Pipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones

Form SCHEDULE 13D Tempest Therapeutics, Filed by: Angel Matthew

Tue, 10 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260210/25977038.html

Form SCHEDULE 13D Tempest Therapeutics, Filed by: Angel Matthew

Tue, 10 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260210/25977038.html

Form 4 Tempest Therapeutics, For: Feb 04 Filed by: Angel Matthew

Fri, 06 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260206/25961952.html

Form 4 Tempest Therapeutics, For: Feb 04 Filed by: Angel Matthew

Fri, 06 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260206/25961952.html

Form 3 Tempest Therapeutics, For: Feb 03 Filed by: Angel Matthew

Fri, 06 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260206/25961936.html

Form 3 Tempest Therapeutics, For: Feb 03 Filed by: Angel Matthew

Fri, 06 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260206/25961936.html

Form 8-K Tempest Therapeutics, For: Feb 03

Fri, 06 Feb 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260206/25961674.html

Form 8-K Tempest Therapeutics, For: Feb 03

Fri, 06 Feb 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260206/25961674.html

Tempest closes acquisition of dual-targeting CAR-T assets

Wed, 04 Feb 2026 16:48:26 -0500

Tempest Therapeutics Inc. (NASDAQ: TPST) completed its acquisition of dual-targeting chimeric antigen receptor T-cell programs from Factor Bioscience Inc. and its affiliates in an all-stock transaction. The deal closed following stockholder approval at the company's annual meeting on January 27.

The acquisition brings Tempest a portfolio of CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD19/BCMA CAR-T therapy. The company's strategic partner plans to fund a biologics license application filing in China for 2027.

Matt Angel joined Tempest as President and CEO following the transaction's completion. "I am excited to join the Tempest team and to have the opportunity to develop this innovative

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets